Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

Published:2023-09 Issue:9 Volume:19 Page:706-713
ISSN:2688-1527
Container-title:JCO Oncology Practice
language:en
Short-container-title:JCO Oncology Practice

Author:

Strati Paolo¹^ORCID,Gregory Tara²³,Majhail Navneet S.⁴⁵^ORCID,Jain Nitin⁶^ORCID

Affiliation:

1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

2. Colorado Blood Cancer Institute, Denver, CO

3. Sarah Cannon Transplant and Cellular Therapy Program at Presbyterian/St Luke's Medical Center, Denver, CO

4. Sarah Cannon, Nashville, TN

5. Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial, Nashville, TN

6. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Practical review of clinical application of #CARTcell for adult patients with heme malignancy

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology (nursing),Health Policy,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/OP.22.00819

Reference59 articles.

1. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

2. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

3. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy

4. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

5. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR T-cell expansion: harmful or helpful?;Blood Advances;2024-06-25

2. Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study;Cardio-Oncology;2024-03-27

3. A dual-luciferase bioluminescence system for the assessment of cellular therapies;Molecular Therapy: Oncology;2024-03

4. Incorporating Immunotherapy with Radiotherapy for Lymphomas;Lymphatics;2023-12-07

5. Temporal patterns of left ventricular systolic and diastolic metrics changes in adult patients with haematological malignancies treated with chimeric antigen receptor (CAR)-T cells: results from the CARdio-Tox prospective study;European Heart Journal - Cardiovascular Imaging;2023-11-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3